A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus


      The purpose of this study was to determine whether the intrauterine contraceptive device (IUD) is effective and safe among women who are infected with the human immunodeficiency virus (HIV).

      Study Design

      We randomly assigned 599 postpartum, HIV-infected women in Zambia to receive either a copper IUD or hormonal contraception and followed them for at least 2 years.


      Women who were assigned randomly to hormonal contraception were more likely to become pregnant than those who were assigned randomly to receive an IUD (rate, 4.6/100 vs 2.0/100 woman-years; hazards ratio, 2.4; 95% CI, 1.3-4.7). One woman who was assigned to the IUD experienced pelvic inflammatory disease (crude rate, 0.16/100 woman-years; 95% CI, 0.004-868); there was no pelvic inflammatory disease among those women who were assigned to hormonal contraception. Clinical disease progression (death or CD4+ lymphocyte count dropping below 200 cells/μL) was more common in women who were allocated to hormonal contraception (13.2/100 woman-years) than in women who were allocated to the IUD (8.6/100 woman-years; hazard ratio, 1.5; 95% CI, 1.04-2.1).


      The IUD is effective and safe in HIV-infected women. The unexpected observation that hormonal contraception was associated with more rapid HIV disease progression requires urgent further study.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • World Health Organization
        Maternal mortality in 2000: estimates developed by WHO, UNICEF and UNFPA. WHO Press, Geneva2004
        • Khan K.S.
        • Wojdyla D.
        • Say L.
        • Gulmezoglu A.M.
        • Van Look P.F.
        WHO analysis of causes of maternal death: a systematic review.
        Lancet. 2006; 367: 1066-1074
        • UNAIDS
        Joint United Nations Programme on HIV/AIDS: 2004 report on the global AIDS epidemic: 4th global report. WHO Press, Geneva2004
        • Central Statistical Office [Zambia]
        • Central Board of Health [Zambia]
        • ORC Macro
        Zambia demographic and health survey 2001-2002. Central Statistical Office, Central Board of Health, and ORC Macro, Calverton (MD)2003
        • World Health Organization
        Strategic approaches to the prevention of HIV infection in infants: report of a WHO meeting, Morges, Switzerland, 20-22 March 2002. WHO Press, Geneva2002
        • Mishell D.
        Intrauterine devices: mechanisms of action, safety, and efficacy.
        Contraception. 1998; 58: 45S-53S
        • Arias R.
        Compelling reasons for recommending IUDs to any woman of reproductive age.
        Int J Fertil Womens Med. 2002; 47: 87-95
        • World Health Organization
        World Health Organization’s second edition of improving access to quality care in family planning: medical eligibility criteria for contraceptive use. WHO Press, Geneva2000
        • Stringer E.M.
        • Sinkala M.
        • Stringer J.S.A.
        • et al.
        Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia.
        AIDS. 2003; 17: 1377-1382
        • World Health Organization
        Guidelines for the management of sexually transmitted infections. WHO press, Geneva2003
        • Stringer J.S.A.
        • Zulu I.
        • Levy J.
        • et al.
        Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.
        JAMA. 2006; 296: 782-793
        • Hager W.
        • Eschenbach D.
        • Spence M.
        • Sweet R.
        Criteria for diagnosis and grading of salpingitis.
        Obstet Gynecol. 1983; 61: 113-114
        • Kennedy K.
        • Trussell J.
        Postpartum contraception and lactation.
        in: Hatcher R.A. Trussel J. Stewart F. Contraceptive technology. 18 ed. Ardent Media, New York2004
        • Allen S.
        • Serufilira A.
        • Gruber V.
        • et al.
        Pregnancy and contraception use among urban Rwandan women after HIV testing and counseling.
        Am J Public Health. 1993; 83: 705-710
        • Thiery M.
        • Van Kets H.
        • Van der Pas H.
        Immediate postplacental IUD insertion: the expulsion problem.
        Contraception. 1985; 31: 331-349
        • Sinei S.K.
        • Morrison C.S.
        • Sekadde-Kigondu C.
        • et al.
        Complications of use of intrauterine devices among HIV-1-infected women.
        Lancet. 1998; 351: 1238-1241
        • Steele F.
        • Diamond I.
        Contraceptive switching in Bangladesh.
        Stud Fam Plann. 1999; 30: 315-328
        • Delbanco T.L.
        • Daley J.
        Through the patient’s eyes: strategies toward more successful contraception.
        Obstet Gynecol. 1996; 88: 41-47
        • Grimes D.A.
        • Schulz K.F.
        Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials.
        Contraception. 1999; 60: 57-63
        • Audet M.C.
        • Moreau M.
        • Koltun W.D.
        • et al.
        Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial.
        JAMA. 2001; 285: 2347-2354
        • Feldblum P.J.
        • Caraway J.
        • Bahamondes L.
        • et al.
        Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: a feasibility of enrollment, continuation, and disease ascertainment.
        Contraception. 2005; 72: 187-191
        • Abrams E.
        Prevention of mother-to-child transmission of HIV: successes, controversies and critical questions.
        AIDS Rev. 2004; 6: 131-143
        • Preble E.A.
        Perinatal transmission in developing countries: new developments, new challenges.
        AIDS Link. 1995; 32: 12-13
        • Reynolds H.W.
        • Janowitz B.
        • Homan R.
        • Johnson L.
        The value of contraception to prevent perinatal HIV transmission.
        Sex Transm Dis. 2006; 33: 350-356
        • Reynolds H.W.
        • Steiner M.J.
        • Cates W.
        Contraception’s proved potential to fight HIV.
        Sex Transm Infect. 2005; 81: 180-188